This is definitely a step in the right direction as far as defending against Triumeq. Best in class PI based single tablet regimen will have a lot of appeal. But it does cut into their main future product (TAF based Stribild) which is now vulnerable to both Triumeq and Prezista/TAF.
Market Data 
Markets 
AI
